PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis
Europe - Euronext Amsterdam - AMS:PHARM - NL0010391025 - Common Stock
1.37 EUR
-0.02 (-1.37%)
Taking everything into account, PHARM scores 5 out of 10 in our fundamental rating. PHARM was compared to 81 industry peers in the Biotechnology industry. PHARM has only an average score on both its financial health and profitability. PHARM has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year PHARM has reported negative net income.
In the past year PHARM had a positive cash flow from operations.
In multiple years PHARM reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: PHARM reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of 0.02%, PHARM is doing good in the industry, outperforming 71.60% of the companies in the same industry.
The Return On Equity of PHARM (0.04%) is better than 75.31% of its industry peers.
The Return On Invested Capital of PHARM (7.14%) is better than 83.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROIC | 7.14% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHARM has a better Profit Margin (0.03%) than 74.07% of its industry peers.
PHARM has a Operating Margin of 10.15%. This is amongst the best in the industry. PHARM outperforms 80.25% of its industry peers.
Looking at the Gross Margin, with a value of 89.90%, PHARM belongs to the top of the industry, outperforming 82.72% of the companies in the same industry.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PHARM is still creating some value.
The number of shares outstanding for PHARM has been increased compared to 1 year ago.
PHARM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHARM has an improved debt to assets ratio.
2.2 Solvency
PHARM has an Altman-Z score of 1.08. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PHARM (1.08) is comparable to the rest of the industry.
The Debt to FCF ratio of PHARM is 2.49, which is a good value as it means it would take PHARM, 2.49 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.49, PHARM belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
PHARM has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.46, PHARM perfoms like the industry average, outperforming 46.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 1.08 |
ROIC/WACC1.27
WACC5.64%
2.3 Liquidity
PHARM has a Current Ratio of 3.16. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
PHARM has a Current ratio of 3.16. This is in the better half of the industry: PHARM outperforms 62.96% of its industry peers.
A Quick Ratio of 2.40 indicates that PHARM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.40, PHARM is in line with its industry, outperforming 55.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 |
3. Growth
3.1 Past
PHARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
PHARM shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.78%.
The Revenue has been growing by 10.64% on average over the past years. This is quite good.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
The Earnings Per Share is expected to grow by 53.48% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y227.95%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y53.48%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y8.97%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PHARM is valuated quite expensively with a Price/Forward Earnings ratio of 25.29.
83.95% of the companies in the same industry are more expensive than PHARM, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PHARM to the average of the S&P500 Index (36.22), we can say PHARM is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHARM is valued cheaply inside the industry as 97.53% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PHARM is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.08 | ||
| EV/EBITDA | 0.79 |
4.3 Compensation for Growth
PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHARM's earnings are expected to grow with 79.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y134.62%
EPS Next 3Y79.43%
5. Dividend
5.1 Amount
PHARM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMS:PHARM (12/2/2025, 5:29:51 PM)
1.37
-0.02 (-1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.71%
Inst Owner ChangeN/A
Ins Owners1.38%
Ins Owner ChangeN/A
Market Cap93.87M
Revenue(TTM)362.27M
Net Income(TTM)100.00K
Analysts88.57
Price Target2.01 (46.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-72.53%
PT rev (3m)-68.28%
EPS NQ rev (1m)50%
EPS NQ rev (3m)90.63%
EPS NY rev (1m)-38.71%
EPS NY rev (3m)3565.57%
Revenue NQ rev (1m)7.7%
Revenue NQ rev (3m)14.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.29 | ||
| P/S | 0.3 | ||
| P/FCF | 2.08 | ||
| P/OCF | 2.05 | ||
| P/B | 0.41 | ||
| P/tB | 0.84 | ||
| EV/EBITDA | 0.79 |
EPS(TTM)0
EYN/A
EPS(NY)0.05
Fwd EY3.95%
FCF(TTM)0.66
FCFY48.09%
OCF(TTM)0.67
OCFY48.67%
SpS4.54
BVpS3.32
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROCE | 9.52% | ||
| ROIC | 7.14% | ||
| ROICexc | 12.54% | ||
| ROICexgc | 32.5% | ||
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% | ||
| FCFM | 14.51% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 4.03% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 6 | ||
| Cash Conversion | 101.53% | ||
| Profit Quality | 52570% | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z | 1.08 |
F-Score7
WACC5.64%
ROIC/WACC1.27
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y227.95%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y53.48%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y8.97%
EBIT growth 1Y357.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.47%
EBIT Next 3Y79.88%
EBIT Next 5Y78.86%
FCF growth 1Y309.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV / PHARM.AS FAQ
What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.
Can you provide the valuation status for PHARMING GROUP NV?
ChartMill assigns a valuation rating of 6 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV?
PHARMING GROUP NV (PHARM.AS) has a profitability rating of 5 / 10.
Can you provide the financial health for PHARM stock?
The financial health rating of PHARMING GROUP NV (PHARM.AS) is 6 / 10.
What is the earnings growth outlook for PHARMING GROUP NV?
The Earnings per Share (EPS) of PHARMING GROUP NV (PHARM.AS) is expected to grow by 227.95% in the next year.